User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Recent Comments
- Update: Biden announced vaccine doses and cash for Africa 1 month 2 weeks ago
- WHO's authorization of mpox vaccine should ease global access 1 month 3 weeks ago
- Ten symptoms of long COVID in children 2 months 1 week ago
- WHO seeks mpox vaccine production surge 2 months 2 weeks ago
Who's online
There are currently 0 users online.
You are here
Moderna says its coronavirus vaccine shows promising results in small trial of elderly patients
Primary tabs
Moderna’s potential coronavirus vaccine generated a promising immune response in elderly patients in an early stage clinical trial, the biotech firm announced Wednesday.
The company tested its vaccine on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said. Each participant received two 100 microgram doses of the vaccine 28 days apart.
The volunteers produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and killer T-cells, Moderna said in its results, which have not yet been published in a peer-reviewed journal. Additionally, the antibodies that were produced were higher than those seen in people who have recovered from Covid-19.
The vaccine also appeared to be well tolerated, with no serious adverse events reported, the company said. Some patients reported fatigue, chills, headaches and pain at the injection site, though the majority of symptoms resolved within two days, the company said. ...
The vaccine from Moderna is one of several in development to fight the coronavirus, which has infected more than 23.9 million people worldwide and killed at least 820,100, according to data compiled by Johns Hopkins University. There are more than 170 vaccines in development worldwide, according to the World Health Organization. At least 31 are in clinical trials, the WHO said. ...
Comments
VBI Vaccines selects two COVID-19 vaccine candidates for human t
(Reuters) - VBI Vaccines Inc said on Wednesday it expected to begin human testing of two of its experimental COVID-19 vaccine candidates at the end of the year.
The two candidates, VBI-2901 and VBI-2902, were selected after three pre-clinical mouse studies induced neutralizing antibodies after a single dose, the company said.
The activity was analyzed using a plaque reduction neutralization test, considered the gold standard for measuring antibodies that can neutralize a virus, the company said.
VBI said its manufacturing partner, Therapure Biomanufacturing, will begin making bulk vaccines in September for use through mid-stage trials.
VBI, which was this month awarded C$56 million ($42 million) by the Canadian government to accelerate its COVID-19 vaccine development program, is one of the many companies racing to produce a safe and effective vaccine against the virus. ...